GleamWall
中文EN

OVID Ovid Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1636651 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-78.0%
TTM net income YoY-18.7%
TTM EPS YoY—
Revenue 3-yr CAGR69.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,700.3%
Net margin-2,971.3%
FCF margin—
EBITDA margin-4,694.6%

Returns

ROE-35.4%
ROA-30.1%
ROIC (approx.)-52.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets10.6%
Debt / equity0.00x
Current ratio11.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.34x
Accruals ratio10.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$7.25M$566,000
R&D expense$25.58M$36.77M
SG&A expense$24.11M$25.68M
Operating income-$42.44M-$61.88M
Pretax income-$17.41M-$26.43M
Income tax$0$0
Net income-$17.41M-$26.43M
EBITDA-$42.17M-$61.27M
EPS (diluted)——
Balance sheet
Cash & equivalents$13.15M$28.23M
Short-term investments$56.48M$26.77M
Current assets$74.37M$55.94M
PP&E, net$252,000$433,000
Intangibles$0$100,000
Total assets$150.93M$92.17M
Current liabilities$8.29M$10.52M
Total liabilities$20.27M$23.94M
Shareholders' equity$130.66M$68.23M
Shares outstanding130.18M71.01M
Cash flow statement
Operating cash flow-$38.33M-$55.96M
Capital expenditure$0$71,000
Free cash flow-$38.33M-$56.03M
Investing cash flow-$49.85M$54.59M
Financing cash flow$75.21M$622,000
Depreciation & amortization$273,000$613,000
Stock-based compensation$4.81M$6.28M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.